title: How far is the horizon? From current targets to future drugs in advanced renal cancer.
abstract: OBJECTIVE
  The proliferative control of renal cell cancer (RCC) via vascular endothelial growth factor and mammalian target of rapamycin inhibition by targeted agents has substantially improved survival rates for RCC patients with metastatic (m) disease. However, the management of mRCC remains challenging because some patients are primarily refractory to the approved targeted agents and most therapies eventually fail because of the development of an intractable drug resistance. Tumor progression is closely related to a persistent or restored proliferation via direct and indirect oncogenic signals. Although the elucidation of cancer cell proliferation in the "-omics era" has revealed an enormous number of new potential targets, a comprehensive overview of the different pathways that might serve as new drug targets has become increasingly complex.
  
  
  RESULTS
  This review highlights the well-trodden pathways in mRCC that are inhibited by targeting agents and describes innovative modes of action within these pathways that are currently not targeted but are under exploration in clinical studies. Additionally, this paper highlights as future drug targets the components of tumor metabolism that supply the tumor cells with nutrition.
  
  
  CONCLUSIONS
  These fundamental insights into RCC proliferation as a key driver of progression are urgently needed to overcome the currently improved but still limited targeted drug success.
authors: Department of Urology, Eberhard-Karls-University Tuebingen, Hoppe-Seyler Strasse 3, 72076, Tuebingen, Germany, Stephan.Kruck@med.uni-tuebingen.de.
authors: Stephan
authors: S
authors: Kruck
authors: Axel S
authors: AS
authors: Merseburger
authors: Arnulf
authors: A
authors: Stenzl
authors: Jens
authors: J
authors: Bedke
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D049109:Cell Proliferation; D018450:Disease Progression; D055808:Drug Discovery / Q000639:trends*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D058990:Molecular Targeted Therapy; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D000970:Antineoplastic Agents; D042461:Vascular Endothelial Growth Factor A; D058570:TOR Serine-Threonine Kinases
references: Urol Oncol. 2009 May-Jun;27(3):238-45
references: 19414111
references: Cell. 2011 Mar 4;144(5):646-74
references: 21376230
references: Urol Int. 2008;80(4):372-7
references: 18587247
references: Cancer Res. 1994 Aug 1;54(15):4233-7
references: 7518352
references: Cancer. 2012 Dec 15;118(24):6152-61
references: 22692704
references: Br J Cancer. 2010 Oct 12;103(8):1255-62
references: 20842112
references: J Cell Physiol. 2011 Feb;226(2):299-308
references: 20857482
references: Cancer. 2010 Feb 15;116(4):780-90
references: 20052733
references: J Pathol. 2010 Jun;221(2):125-38
references: 20225241
references: Invest New Drugs. 2006 Jul;24(4):263-80
references: 16683072
references: Nat Med. 2003 Jun;9(6):669-76
references: 12778165
references: BJU Int. 2012 Dec;110(11 Pt B):E771-7
references: 23134582
references: Science. 1956 Aug 10;124(3215):269-70
references: 13351639
references: Oncol Rep. 2010 Jan;23(1):159-63
references: 19956876
references: Nat Rev Cancer. 2003 Oct;3(10):721-32
references: 13130303
references: World J Urol. 2011 Feb;29(1):121-6
references: 20512580
references: Oncotarget. 2012 Jan;3(1):84-97
references: 22289741
references: Expert Rev Anticancer Ther. 2012 Dec;12(12):1503-5
references: 23253216
references: J Bioenerg Biomembr. 2007 Jun;39(3):235-41
references: 17665292
references: J Pathol. 2012 Jun;227(2):146-56
references: 22362593
references: Cell. 2006 Sep 8;126(5):955-68
references: 16959574
references: Clin Cancer Res. 2009 Dec 15;15(24):7582-7592
references: 19996202
references: Expert Rev Anticancer Ther. 2012 Jun;12(6):777-85
references: 22716494
references: J Clin Oncol. 2004 Dec 15;22(24):4991-5004
references: 15611513
references: FASEB J. 2004 Feb;18(2):338-40
references: 14657001
references: J Biol Chem. 2011 Dec 23;286(51):43634-43643
references: 22030397
references: Cancer Res. 2011 Jan 1;71(1):13-8
references: 21199794
references: Am J Clin Oncol. 2011 Dec;34(6):628-35
references: 20805739
references: Cancer Res. 2010 Feb 1;70(3):1053-62
references: 20103629
references: Cancer Cell. 2007 Jul;12(1):9-22
references: 17613433
references: Science. 2009 May 22;324(5930):1029-33
references: 19460998
references: Eur Urol. 2009 Apr;55(4):851-63
references: 19155123
references: J Exp Med. 2012 Feb 13;209(2):211-5
references: 22330683
references: Lancet Oncol. 2012 Oct;13(10):1055-62
references: 22959186
references: Development. 1998 May;125(9):1591-8
references: 9521897
references: J Biol Chem. 2008 Dec 12;283(50):34495-9
references: 18945681
references: Nature. 2002 Dec 19-26;420(6917):860-7
references: 12490959
references: J Pathol. 2002 Dec;198(4):502-10
references: 12434420
references: Cancer Biol Ther. 2012 Sep;13(11):1102-11
references: 22895065
references: Mol Cancer. 2011 Jul 26;10:90
references: 21791089
references: J Clin Oncol. 2012 Oct 10;30(29):3633-9
references: 22965953
references: Nature. 2000 Nov 16;408(6810):307-10
references: 11099028
references: BJU Int. 2012 May;109(10):1565-70
references: 21981759
references: BJU Int. 2012 Feb;109(4):634-8
references: 21711439